Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cidara

Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Seven-Year High

Shares of Cidara Therapeutics surged to a seven-year high Wednesday on plans to expand testing for its non-vaccine flu prevention drug.

Investors Business Daily

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

Cidara Therapeutics Doubles As A Universal Flu Shot Becomes A Closer Reality

Cidara Therapeutics Doubles As A Universal Flu Shot Becomes A Closer Reality

Cidara Therapeutics stock skyrocketed on Monday after the company presented a promising update for its universal flu shot.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.

FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza

inkl

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

European Medicines Agency

US Food and Drug Administration

IDEAYA Biosciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play